Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster viewing 03

171P - Clinical significance of prostate volume and testosterone reduction on lower urinary tract symptoms in patients with prostate cancer undergoing androgen deprivation therapy

Date

03 Dec 2022

Session

Poster viewing 03

Topics

Tumour Site

Genitourinary Cancers

Presenters

Jin Cho

Citation

Annals of Oncology (2022) 33 (suppl_9): S1495-S1502. 10.1016/annonc/annonc1125

Authors

J.S. Cho1, Y.A. Cho2, C.K. Park3

Author affiliations

  • 1 Urology, HUMC - Hallym University Sacred Heart Hospital (HUSHH), 14068 - Anyang/KR
  • 2 Pathology Department, Hallym University Medical Center (HUMC)-Hallym University Sacred Heart Hospital, 14068 - Anyang/KR
  • 3 Department Of Pathology, Yonsei University, 03722 - Seoul/KR

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 171P

Background

To investigate the effect of both prostate volume and serum testosterone changes on lower urinary tract symptoms in patients with prostate cancer undergoing androgen deprivation therapy.

Methods

A total of 167 patients who received androgen deprivation therapy for prostate cancer treatment from January 2010 to August 2020 were enrolled in this retrospective study. Changes in the International Prostate Symptom Score (IPSS) in the patient groups stratified by prostate volume and the amount of testosterone reduction were assessed every 4 weeks until 12 weeks after androgen deprivation therapy initiation. Longitudinal mixed models were used to assess the adjusted effects of prostate volume and testosterone reduction on IPSS change.

Results

All mean values of IPSS-total score (IPSS-total), voiding subscore (IPSS-vs), and storage subscore (IPSS-ss) significantly decreased from baseline to week 12 in both patients with small (<33 mL) and large (≥33 mL) prostates. The mean values of IPSS-total, IPSS-vs, and IPSS-ss similarly decreased in patients with large prostate with a baseline IPSS-total of ≥13. However, in those with small prostate, IPSS-ss specifically remained unchanged, while IPSS-total and IPSS-vs significantly decreased. In addition, only in patients with small prostate (<33 mL), patients with lesser testosterone reduction (<Δ400 ng/dL) showed greater improvement in IPSS-ss by 6.3% compared with those with greater testosterone reduction (≥ Δ400 ng/dL).

Conclusions

Although androgen deprivation therapy generally improves lower urinary tract symptoms, it may not improve storage symptoms in patients with relatively small prostate and greater testosterone reduction. Our finding suggests that testosterone may influence lower urinary tract symptoms in these patients.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.